Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73,819,979
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
5,303,151
-
Shares change
-
-916,357
-
Total reported value, excl. options
-
$3,177,608
-
Value change
-
-$311,761
-
Number of buys
-
16
-
Number of sells
-
-20
-
Price
-
$0.6003
Significant Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q2 2025
55 filings reported holding RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share as of Q2 2025.
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,303,151 shares
of 73,819,979 outstanding shares and own 7.2% of the company stock.
Largest 10 shareholders include Driehaus Capital Management LLC (740,006 shares), ACADIAN ASSET MANAGEMENT LLC (619,479 shares), BlackRock, Inc. (508,000 shares), AdvisorShares Investments LLC (396,514 shares), VANGUARD GROUP INC (364,077 shares), GEODE CAPITAL MANAGEMENT, LLC (302,354 shares), DEUTSCHE BANK AG\ (224,846 shares), Corient Private Wealth LLC (206,667 shares), UBS Group AG (180,471 shares), and PARSONS CAPITAL MANAGEMENT INC/RI (163,336 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.